Progen Pharmaceuticals, of Brisbane, Australia, appointed James Garner vice president of medical and clinical affairs, and John Devlin vice president of manufacturing operations.

Protalix BioTherapeutics Inc., of Carmiel, Israel, appointed Ernest Beutlerto to its scientific advisory board.

ReceptIcon, of Copenhagen, Denmark, appointed Anders Vedin chairman of its board of directors.

Seattle Genetics, of Bothell, Wash., added John P. McLaughlin and Daniel G. Welch to its board of directors.

Shire plc, of Cambridge, UK, appointed Hugh Cole vice president of business development.

Sofinnova Ventures, of San Francisco, named David Kabakoff executive in residence at the company's San Diego office.

Somanetics Corp., of Troy, Mich., added John P. Jumper to its board of directors.

Targacept Inc., of Winston-Salem, N.C., added Ralph Snyderman to its board of directors.

Transave Inc., of Monmouth Junction, N.J. appointed Michio "Mich" Soga its chief financial officer.

Trius Therapeutics Inc., of San Diego, named Kenneth F. Bartizal chief development officer.

VaxInnate, of Cranbury, N.J., appointed Andrew T. Drechsler chief financial officer and Edward J. Arcuri chief operations officer.

Xechem International Inc., of New Brunswick, N.J., named H. Scott English internal director of investor relations and Benjamin S. White III the director of finance and accounting.

Zogenix Inc., of San Diego, appointed David Nassif executive vice president and chief financial officer.